TLDR
- Sanofi reveals €1 billion share repurchase program for 2026, starting February 3
- Fourth-quarter 2025 operating profit rose 12.7% to €2.34 billion, beating forecasts
- Company projects high single-digit revenue growth in 2026 from immunology and vaccines
- New buyback follows €5 billion repurchase completed in 2025
- Dupixent generates approximately 30% of Sanofi’s total revenue
Sanofi is returning cash to shareholders with a new €1 billion share buyback program. The repurchase initiative runs from February 3 through December 31, 2026.
The company has finalized an agreement with an investment services firm to manage the buyback. At current rates, the program equals roughly $1.20 billion.
This announcement follows impressive fourth-quarter performance. Operating profit jumped 12.7% to €2.34 billion in Q4 2025. Revenue reached €11.3 billion, surpassing analyst predictions.
Non-GAAP earnings per share came in at €1.53, beating estimates by €0.06. These results demonstrate Sanofi’s ability to maintain profitability in a competitive pharmaceutical market.
Strong Performance Drives Buyback Decision
Management expects high single-digit sales growth throughout 2026. The immunology and vaccine divisions will power this expansion.
Dupixent continues as the company’s flagship product. This blockbuster drug accounts for about 30% of all Sanofi sales. It remains the top revenue generator in the product portfolio.
The company’s gross margin stands at 71.32%. Operating margin reached 21.82%. These profitability metrics support the decision to return capital to investors.
Sanofi completed a €5 billion buyback program in 2025. That larger initiative included a €3 billion off-market transaction with L’Oréal. The cosmetics giant had been a longtime Sanofi shareholder.
Geographic and Strategic Focus
The United States generates about 45% of Sanofi’s revenue. European markets contribute roughly 20% of sales. China accounts for 6% of total revenue.
Sanofi is reshaping its business model. The company is spinning off its consumer health division. This allows management to focus on higher-growth therapeutic areas.
Immunology, vaccines, and rare diseases now receive priority. These segments offer better long-term growth prospects than consumer products.
The company maintains solid financial fundamentals. Its current ratio sits at 1.09. The debt-to-equity ratio of 0.29 indicates conservative leverage.
Three-year revenue growth stands at 4.2%. This steady expansion backs management’s capital allocation strategy.
Wall Street assigns Sanofi a Moderate Buy rating. Two analysts recommend purchasing shares. Three analysts suggest holding current positions.
The average analyst price target is $79.18. This represents potential upside of 67.51% from recent trading levels. Market capitalization totals €114.17 billion.
Institutional investors control 9.96% of outstanding shares. The P/E ratio of 11.52 trades near historical lows. The P/S ratio of 2.17 also sits below long-term averages.
Sanofi begins executing the €1 billion share repurchase on February 3, 2026.
